| 摘要 |
<p>The invention is directed to novel antibodies, which comprise single domain binding sites. The antibodies can be bivalent or multivalent, and can be bispecific. The invention is further directed to monospecific and bispecific antibodies that bind to mPDGFRalpha. The antibodies can be administered alone or in combination with anti- angiogenic or anti-neoplastic drugs.</p> |
